immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Flow cytometry were used to explore univariate associations of baseline peripheral blood immune profile with week 12 overall response.
Conclusion:
Pembrolizumab with paclitaxel or capecitabine is safe and clinically active. Both regimens were lymphodepleting, highlighting the competing immunostimulatory versus lymphotoxic effects of cytotoxic chemotherapy. CD-Chex Plus was used to ensure frequencies of major cell populations of interests fall into mean+/- 3SD in the Levey-Jennings plots.